Companies › TCM Biotech International
1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| U101 Pentosan polysulfate sodium - likely works through glycosaminoglycan layer restoration and | – | Phase 3 | Recurrent Urinary Tract Infections in Women | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07184827 | U101 | Phase 3 | Recurrent Urinary Tract Infections in Women | Infectious disease | Jun 2028 |
No annotated target.
–
Vivacelle Bio Ansun Biopharma SymBio Pharmaceuticals F2G Baxis Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.